CABA · Cabaletta Bio, Inc. · Share Buybacks
$1.33
-0.12 (-8.28%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— cleared Nov 5, 2026
The latest filing states the doubt was alleviated.
“As disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, we had previously identified conditions that raised substantial doubt about our ability to continue as a going concern. During the quarter ended September 30, 2026, we raised additional funds through the exercise of common stock warrants for proceeds of $115.0 million and sold 1.9 million shares pursuant to the 2025 ATM Program for net proceeds of $6.0 million. As a result of these cash raises, the conditions that previously raised substantial doubt are no longer present.”View the 10-Q filed Nov 5, 2026
Market Cap
$286.91M
Shares
215.72M
Volume · Nov 12
3.73M
Avg daily vol (3M)
5.32M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-08-07 | — | $150,000,000 | — | — | 10-Q , filed 2025-11-10 |
Key facts
CIK
1759138
CUSIP
12674W109
13F (30d)
80 filings
71 filers
Visit website
Investor relations